TGFBR2 Tyr259 Antibody , Cy7 Conjugated

Cy7

Cy7

7048

Tyr259

P37173

Cytoplasm

IF(IHC-P)

anticorps

Polyclonal

1ug per 1ul

743nm/767nm

250-270/567

TGFBR2 Tyr259

Phosphorylation

Human, Mouse, Rat

IF(IHC-P)(1:50-200)

Polyclonal antibody

Conjugated Primary Antibodies

Rabbit (Oryctolagus cuniculus)

This antibody was purified via Protein A.

TGFBR2 Tyr259 Polyclonal Antibody , Cy7 Conjugated

This is a highly specific antibody against TGFBR2 Tyr259.

These antibodies are excite for emission at 650 nm and detected at a 676 nm wavelengths.

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

KLH conjugated synthesised phosphopeptide derived from human TGF beta Receptor II around the phosphorylation site of Tyr259

If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Keep the antibody in an aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store refrigerated at 2 to 8 degrees Celcius for up to 1 year.

AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta receptor type-2; TGF-beta type II receptor; Transforming growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II; TGFBR2

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.